Biotech News
Related news
MXCTMaxCyte2026-11-10 11:00 EST
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
MXCTMaxCyte2026-10-28 12:06 EST
MaxCyte to Participate in Three Upcoming Investor Conferences
NTLAIntellia2026-10-13 11:30 EST
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
EDITEditas Medicine2026-09-08 11:00 EST
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
CRSPCRISPR Therapeutics2026-11-02 13:00 EST
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
CRSPCRISPR Therapeutics2026-10-19 20:05 EST
CRISPR Therapeutics Announces Chief Financial Officer Transition
SRPTSarepta Therapeutics2026-11-05 21:05 EST
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
MGTXMeiraGTx2026-09-23 12:00 EST
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
SRPTSarepta Therapeutics2026-08-05 20:05 EST
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
OCGNOcugen2026-10-06 11:02 EST
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
MaxCyte
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...
Recent company news
MXCTMaxCyte2026-11-10 11:01 EST
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
MXCTMaxCyte2026-11-10 11:00 EST
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
MXCTMaxCyte2026-10-28 12:06 EST
MaxCyte to Participate in Three Upcoming Investor Conferences
MXCTMaxCyte2026-10-14 12:05 EST
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
MXCTMaxCyte2026-09-23 12:05 EST
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
Stock data
- Close
- 1.28 USD
- Market cap
- 131.76M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
